Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.

Volz AK, Dingemanse J, Krause A, Lehr T.

Pharm Res. 2019 Dec 10;37(1):2. doi: 10.1007/s11095-019-2723-3.

PMID:
31823033
2.

Modelling pharmacokinetics and pharmacodynamics of the selective S1P1 receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients.

Lott D, Juif PE, Dingemanse J, Krause A.

Br J Clin Pharmacol. 2019 Nov 22. doi: 10.1111/bcp.14182. [Epub ahead of print]

PMID:
31756016
3.

The Case for an Unblinded Modeler in Early Clinical Development.

Krause A, Henrich A, Dingemanse J.

J Clin Pharmacol. 2019 Sep 25. doi: 10.1002/jcph.1526. [Epub ahead of print]

PMID:
31552685
4.

Simultaneous change of wood mass and dimension caused by moisture dynamics.

Nopens M, Riegler M, Hansmann C, Krause A.

Sci Rep. 2019 Jul 16;9(1):10309. doi: 10.1038/s41598-019-46381-8.

5.

Humoral and Cellular Patterns of Early Endothelial Progenitor Cells in Relation to the Cardiovascular Risk in Axial Spondylarthritis.

Patschan S, Vogt M, Bakhtiari D, Bramlage CP, Henze E, Muller GA, Krause A, Patschan D.

J Clin Med Res. 2019 Jun;11(6):391-400. doi: 10.14740/jocmr3441w. Epub 2019 May 10.

6.

[Comorbidities].

Krüger K, Krause A.

Z Rheumatol. 2019 Apr;78(3):218-220. doi: 10.1007/s00393-019-0609-8. German. No abstract available.

PMID:
30941588
7.

Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873.

Krause A, Kloft C, Huisinga W, Karlsson M, Pinheiro J, Bies R, Rogers J, Mentré F, Musser BJ; ASA Special Interest Group on Statistics and Pharmacometrics/ASA Special Interest Group on Statistics and Pharmacometrics (SIG SxP).

Pharm Stat. 2019 May;18(3):278-281. doi: 10.1002/pst.1940. Epub 2019 Apr 1. No abstract available.

PMID:
30932340
8.

Tomographic analysis of siliceous particulates in Australian turpentine wood (Syncarpia glomulifera) through X-ray micro-computed tomography.

Koddenberg T, Krause KC, Krause A.

Micron. 2019 Feb;117:22-28. doi: 10.1016/j.micron.2018.10.006. Epub 2018 Oct 28.

PMID:
30447491
9.

Generalization and Search in Risky Environments.

Schulz E, Wu CM, Huys QJM, Krause A, Speekenbrink M.

Cogn Sci. 2018 Nov;42(8):2592-2620. doi: 10.1111/cogs.12695. Epub 2018 Nov 2.

PMID:
30390325
10.

Land-use emissions play a critical role in land-based mitigation for Paris climate targets.

Harper AB, Powell T, Cox PM, House J, Huntingford C, Lenton TM, Sitch S, Burke E, Chadburn SE, Collins WJ, Comyn-Platt E, Daioglou V, Doelman JC, Hayman G, Robertson E, van Vuuren D, Wiltshire A, Webber CP, Bastos A, Boysen L, Ciais P, Devaraju N, Jain AK, Krause A, Poulter B, Shu S.

Nat Commun. 2018 Aug 7;9(1):2938. doi: 10.1038/s41467-018-05340-z.

11.

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.

Park W, Božić-Majstorović L, Milakovic D, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Molina FFC, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Garmish O, Linde T, Rekalov D, Hrycaj P, Krause A, Fomina N, Piura O, Abello-Banfi M, Suh CH, Shim SC, Lee SJ, Lee SY, Kim SH, Yoo DH.

MAbs. 2018 Aug/Sep;10(6):934-943. doi: 10.1080/19420862.2018.1487912. Epub 2018 Jul 16.

12.

Strategies for the treatment of HBV/HDV.

Krause A, Haberkorn U, Mier W.

Eur J Pharmacol. 2018 Aug 15;833:379-391. doi: 10.1016/j.ejphar.2018.06.030. Epub 2018 Jun 21. Review.

PMID:
29935174
13.

Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity.

Schäfer VS, Weiß K, Krause A, Schmidt WA.

Clin Rheumatol. 2018 Jul;37(7):1835-1844. doi: 10.1007/s10067-018-4093-3. Epub 2018 Apr 14.

PMID:
29656375
14.

Large uncertainty in carbon uptake potential of land-based climate-change mitigation efforts.

Krause A, Pugh TAM, Bayer AD, Li W, Leung F, Bondeau A, Doelman JC, Humpenöder F, Anthoni P, Bodirsky BL, Ciais P, Müller C, Murray-Tortarolo G, Olin S, Popp A, Sitch S, Stehfest E, Arneth A.

Glob Chang Biol. 2018 Jul;24(7):3025-3038. doi: 10.1111/gcb.14144. Epub 2018 Apr 16.

PMID:
29569788
15.

Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.

Krause A, Zisowsky J, Dingemanse J.

Pulm Pharmacol Ther. 2018 Apr;49:140-146. doi: 10.1016/j.pupt.2018.02.005. Epub 2018 Feb 28.

PMID:
29501590
16.

Confidence and Prediction Intervals for Pharmacometric Models.

Kümmel A, Bonate PL, Dingemanse J, Krause A.

CPT Pharmacometrics Syst Pharmacol. 2018 Jun;7(6):360-373. doi: 10.1002/psp4.12286. Epub 2018 Mar 25.

17.

Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis.

Krause A, D'Ambrosio D, Dingemanse J.

J Dermatol Sci. 2018 Feb;89(2):136-145. doi: 10.1016/j.jdermsci.2017.11.003. Epub 2017 Nov 20.

PMID:
29174115
18.

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.

Baganz L, Richter A, Kekow J, Bussmann A, Krause A, Stille C, Listing J, Zink A, Strangfeld A.

Rheumatol Int. 2018 Apr;38(4):579-587. doi: 10.1007/s00296-017-3870-7. Epub 2017 Nov 16.

19.

Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.

Hofmann H, Fingerle V, Hunfeld KP, Huppertz HI, Krause A, Rauer S, Ruf B; Consensus group.

Ger Med Sci. 2017 Sep 5;15:Doc14. doi: 10.3205/000255. eCollection 2017.

20.

Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod.

Lott D, Lehr T, Dingemanse J, Krause A.

Clin Pharmacol Ther. 2018 Jun;103(6):1083-1092. doi: 10.1002/cpt.877. Epub 2017 Oct 27.

PMID:
28913826

Supplemental Content

Loading ...
Support Center